StockData
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. (WHWK) stock

WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.08+0.07 (+2.33%)

Close on Nov 17, 2026Market cap $175.59MP/E –Yield –

Whitehawk Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Whitehawk Therapeutics's gross margin for the twelve months ending Dec 31, 2025 was 89.4%. For fiscal 2025 it was 89.4%, against 88.4% the year before. The highest annual figure on record is 100.0% in fiscal 2021.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202589.4%+1.0
FY2024Dec 31, 202488.4%−0.1
FY2023Dec 31, 202388.5%−2.8
FY2022Dec 31, 202291.2%−8.8
FY2021Dec 31, 2021100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2025Mar 31, 202589.4%+1.5
Q4 FY2024Dec 31, 202489.1%+3.7
Q3 FY2024Sep 30, 202488.9%+0.5
Q2 FY2024Jun 30, 202487.4%−2.0
Q1 FY2024Mar 31, 202487.8%−3.2
Q4 FY2023Dec 31, 202385.3%−10.4
Q3 FY2023Sep 30, 202388.3%+2.3
Q2 FY2023Jun 30, 202389.4%−0.7
Q1 FY2023Mar 31, 202391.0%−1.3
Q4 FY2022Dec 31, 202295.8%−4.2
Q3 FY2022Sep 30, 202286.0%–
Q2 FY2022Jun 30, 202290.1%–
Q1 FY2022Mar 31, 202292.2%–
Q4 FY2021Dec 31, 2021100.0%–

More Whitehawk Therapeutics figures

See a number that looks wrong?